A new research paper shows that, in some ways, U.S. prescription drug spending is not necessarily all that high.

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity and type-2 diabetes ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market size during the study period (2020–2034). This anticipated ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

"We have launched Wegovy in 25 countries, including three in that last month, reflecting greater supply availability," ...

The type of bankruptcy allows WeightWatchers to continue operating while it restructures its assets and fights to continue ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

The diet company formerly known as WeightWatchers has filed for bankruptcy after its 62-year-old business model was put under ...